EON

Top Statistician Says You Cant Discount Higher Risks With Vytorin

Seattle, WA- There have been a number of different news reports recently that have said that there is no credible risk for patients that are taking Vytorin and those patients that have reported cancers, while taking Vytorin.

Despite these other reports, a Top cancer researcher and statistician is saying that you cannot rule out increased risk for patients that use Vytorin.

In a new study that is being revealed in the New England Journal of Medicine, researcher Thomas Fleming of the University of Washington says that there are clinically important increases that cannot be rule out by the current data.

Fleming argues that the risk of Vytorin and cancer death should have been kept quiet, and studied without the inflammatory risk of every patient on Vytorin becoming alarmed and experiencing high levels of anxiety.

The clear evidence about Vytorin is contaminated by media and public attention, and Fleming feels that the safety and efficacy of the drug is not going to be easy to study or solve.

The study of the drug should have been done under strict controls and with the normal institutional sharing but not sharing about risks with the cancer process with the patients and general public until those risks have been validates..

Dr. Fleming and his new editorial spell trouble for the makers of Vytorin, and the overall success of the drug. The cancer risk rumor continue to plague the drugs, and sales, once robust have been easing off in the face of the cancer link rumors.